<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Urban, Stephan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Myrcludex B Therapy Reduced HBV DNA and HDV RNA in Phase 2a Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">Chronic hepatitis B virus (HBV) infection is rarely cured with current therapies, and there is no effective therapy for hepatitis D virus (HBD) coinfection. Myrcludex B is a first-in-class entry inhibitor that inactivates the HBV and HDV receptor sodium taurocholate cotransporting polypeptide. This article discusses a phase 2a study evaluating the safety, tolerability, and antiviral efficacy of Myrcludex B.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>